Cefazolin pharmacokinetics in premature infants.

ABSTRACT:

Objective

Pharmacokinetic (PK) data to guide cefazolin dosing in premature infants are virtually non-existent. Therefore, we aimed to characterize cefazolin PK in infants aged ≤32 weeks of gestation at birth.

Study design

We conducted a prospective, open-label PK and safety study of cefazolin in infants ≤32 weeks gestation from a University Medical Center. We administered intravenous cefazolin and collected both timed and scavenged blood samples. We analyzed data using non-linear mixed effect modeling and simulated several dosage regimens to achieve target concentrations against methicillin-susceptible Staphylococcus aureus.

Results

We analyzed 40 samples from nine infants and observed that premature infants had lower clearance and greater volume of distribution for c

SUBMITTER: Balevic SJ 

PROVIDER: S-EPMC6713589 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature